Stocktoria
GT Biopharma, Inc. GTBP
GT Biopharma, Inc. (GTBP) earns a Piotroski F-score of 2/9 (weak financial health). It pays a dividend yielding 1.26% (safety: safe).
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| GTBP | GT Biopharma, Inc. | 2/9 | — | — | — |
| JNJ | JOHNSON & JOHNSON | 4/9 | — | 22.9 | +6% |
| LLY | ELI LILLY & Co | 7/9 | — | 55.1 | +44.7% |
| MRK | Merck & Co., Inc. | 4/9 | — | 17.4 | +1.3% |
| PFE | PFIZER INC | 4/9 | — | 17.8 | -1.6% |
| ABBV | AbbVie Inc. | 7/9 | -0.34 | 105.9 | +8.6% |
| BMY | BRISTOL MYERS SQUIBB CO | 7/9 | — | 16.7 | -0.2% |
About GT Biopharma, Inc.
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
FAQ
Is GTBP financially healthy?
GT Biopharma, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does GTBP pay a dividend, and is it safe?
Yes. GT Biopharma, Inc. pays a dividend yielding about 1.26% with a -0.8% payout ratio, rated “safe” for safety.
How profitable is GTBP?
In FY2025, GT Biopharma, Inc. had a return on equity of -490.0%.
What is the analyst price target for GTBP?
The average Wall-Street price target for GT Biopharma, Inc. is $3.00, about 893.0% above the recent price, from 1 analysts.
Is GTBP a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on GT Biopharma, Inc.: a Piotroski F-score of 2/9, a dividend yield of 1.26%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.